Northfield Laboratories Names Alan L. Heller to Board Of Directors
February 27 2006 - 8:11PM
Business Wire
Northfield Laboratories Inc. (Nasdaq: NFLD) announced today the
appointment of Alan L. Heller, a healthcare industry veteran, to
its Board of Directors. Mr. Heller has a long and distinguished
career in the healthcare industry. Most recently he was President
and Chief Executive Officer of American Pharmaceutical Partners, a
company that develops, manufactures and markets branded and generic
injectable pharmaceutical products and recently merged with
American Bioscience Inc. Prior to APP, Mr. Heller was an investment
advisor on life science transactions to One Equity Partners, a
private equity arm of JP Morgan Chase/Bank One. Previously, Mr.
Heller served as Senior Vice President and President Global Renal
operations at Baxter Healthcare Corporation, where he had
responsibility for global operations of the Renal and Transfusion
Therapies divisions as well as global manufacturing and the office
of the Chief Scientific Officer. Prior to joining Baxter, Mr.
Heller spent 23 years at G.D. Searle. He served in a number of
positions in general management, sales, marketing, business
development and finance before being named Co-President and Chief
Operating Officer, with responsibility for all commercial
operations worldwide. Subsequent to Searle's acquisition by
Pharmacia, Mr. Heller was Executive Vice President and President,
Searle Operations, overseeing the Searle integration into
Pharmacia, and also serving as a member of the Pharmacia Management
Committee. "We are delighted to welcome Al Heller to our Board. His
extensive experience will be of great value to Northfield," said
Steven A. Gould, M.D., Chairman and Chief Executive Officer. About
Northfield Laboratories Northfield Laboratories Inc. is a leader in
developing an oxygen-carrying resuscitative fluid, PolyHeme(R), for
the treatment of urgent, large volume blood loss in trauma and
resultant surgical settings. PolyHeme(R) is a solution of
chemically modified human hemoglobin that requires no cross
matching and is therefore compatible with all blood types. It has a
shelf life in excess of 12 months. Enrollment is currently underway
in a pivotal Phase III trial of PolyHeme(R) beginning in the
pre-hospital setting. For further information, visit
www.northfieldlabs.com. This press release contains forward-looking
statements concerning, among other things, Northfield's future
business plans and strategies and clinical and regulatory
developments affecting our PolyHeme(R) blood substitute product.
These forward-looking statements are identified by the use of such
terms as "intends," "expects," "plans," "estimates," "anticipates,"
"should," "believes" and similar terms. These forward-looking
statements involve inherent risks and uncertainties. Our actual
results may therefore differ materially from those predicted by the
forward-looking statements because of various factors and possible
events, including our ability to obtain FDA approval to market
PolyHeme commercially, the availability of capital to finance our
clinical trials and ongoing business operations, our ability to
obtain adequate supplies of raw materials and to manufacture
PolyHeme in commercial quantities, our ability to market PolyHeme
successfully, the possibility that competitors will develop
products that will render PolyHeme obsolete or non-competitive, our
ability to protect our intellectual property rights, the
possibility that we may be subject to product liability claims and
other legal actions, our dependency on a limited number of key
personnel, the uncertainty of third party reimbursement for our
product and other risks and uncertainties described from time to
time in our periodic reports filed with the Securities and Exchange
Commission, including our most recently filed quarterly report on
Form 10-Q and annual report on Form 10-K. These forward- looking
statements speak only as of the date of this press release. We do
not undertake any obligation to update or publicly release any
revisions to forward-looking statements to reflect events,
circumstances or changes in expectations after the time such
statement is made. All subsequent written and oral forward-looking
statements attributable to Northfield or any person acting on our
behalf are qualified by this cautionary statement.
Northfield labs (NASDAQ:NFLD)
Historical Stock Chart
From Jul 2024 to Aug 2024
Northfield labs (NASDAQ:NFLD)
Historical Stock Chart
From Aug 2023 to Aug 2024